For this reason, the A2AR–D2R heteroreceptor complex represents a new therapeutic target for disorders treated with drugs interacting with the D2R, such as neurodegenerative diseases, schizophrenia, and drug addiction (Borroto-Escuela et al., 2016b). Here, DRD2 is linked to schizophrenia.